Long-term effects of finasteride on prostate tissue composition

Urology

Volumn 53, Issue 3, 1999, Pages 574-580

  Marks, Leonard S ^a,c   Partin, Alan W ^b   Dorey, Frederick J ^a   Epstein, Jonathan I ^b   Garris, Joel B ^d   Macairan, Maria Luz ^c   Shery, Erlinda D ^c   Santos, Paul Bryan ^c   Stoner, Elizabeth ^b   DeKernion, Jean B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Urological Sci Research Foundation   (United States)

^d Brotman Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG SELECTIVITY; HISTOPATHOLOGY; HUMAN; LONG TERM CARE; MALE; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; SYMPTOM; TREATMENT OUTCOME;

DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATIC HYPERPLASIA; TIME FACTORS;

EID: 0033104391     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00567-6     Document Type: Article

References (34)

1. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia Finasteride Long-Term Efficacy and Safety Study Group . N Engl J Med. 338:1998;557-563.
2. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 43:1994;284-292.
3. Ekman P. Maximum efficacy of finasteride is obtained within 6 months and maintained over 6 years. Follow-up of the Scandinavian Open-Extension Study. The Scandinavian Finasteride Study Group. Eur Urol. 33:1998;312-317.
4. Moore E., Bracken B., Bremner W., et al. Proscar five-year experience . Eur Urol. 28:1995;304-309.
5. Marberger M.J. Long-term effects of finasteride in patients with benign prostatic hyperplasia a double-blind, placebo-controlled, multicenter study. PROWESS Study Group . Urology. 51:1998;677-686.
6. Marks L.S., Partin A.W., Gormley G.J., et al. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia. J Urol. 157:1997;2171-2178.
7. Rittmaster R.S., Norman R.W., Thomas L.N., et al. Evidence for atrophy and apoptosis in the prostates of men given finasteride. Clin Endocrinol Metab. 81:1996;814-819.
8. Guess H.A., Heyse J.F., Gormley G.J., et al. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia results from the North American phase III clinical trial . Urol Clin North Am. 20:1993;627-636.
9. and the Finasteride PSA Study Group , Oesterling J.E., Roy J., Agha A., et al. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer effects of finasteride . Urology. 51:(suppl 4A):1998;58-63.
10. Tempany C.M.C., Partin A.W., Zerhouni E.A., et al. The influence of finasteride on the volume of the peripheral and periourethral zones of the prostate in men with benign prostatic hyperplasia. Prostate. 22:1993;39-42.
11. Tewari A., Shinohara K., Narayan P. Transition zone volume and transition zone ratio predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients . Urology. 45:1995;258-265.
12. Huggins C., Stevens R.A. The effect of castration on benign hypertrophy of the prostate in man. J Urol. 43:1940;705-714.
13. Gormley G.J., Stoner E., Bruskewitz R.C., et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 327:1992;1185-1191.
14. Geller J., Bora R., Roberts T., et al. Treatment of benign prostatic hypertrophy with hydroxyprogesterone caproate. JAMA. 193:1965;115-122.
15. Scott W.W., Wade J.C. Medical treatment of benign nodular prostatic hyperplasia with cyproterone acetate. J Urol. 101:1969;81-85.
16. Wendel E.F., Brannen G.E., Putong P.B., et al. The effect of orchiectomy and estrogens on benign prostatic hyperplasia. J Urol. 108:1972;116-119.
17. Peters C.A., Walsh P.C. The effect of naferelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med. 317:1987;599-604.
18. Harada M., Kinoshita Y., Masatoshi M. Histological evaluation of benign prostatic hyperplasia treated by long-term administration of chlormadinone acetate (CMA). Prostate. 25:1994;147-155.
19. Montironi R., Valli M., Fabris G. Treatment of benign prostatic hyperplasia with 5-α-reductase inhibitor morphological changes in patients who fail to respond . J Clin Pathol. 49:1996;324-328.
20. Svindland A., Eri L.M., Tveter K.J. Morphometry of benign prostatic hyperplasia during androgen suppressive therapy. Scand J Urol Nephrol. 179:(suppl):1996;113-117.
21. Laroque P.A., Prahalada S., Molon-Noblot S., et al. Quantitative evaluation of glandular and stromal compartments in hyperplastic dog prostates effect of 5-alpha reductase inhibitors . Prostate. 27:1995;121-128.
22. Prahalada S., Rhodes L., Grossman S.J., et al. Morphological and hormonal changes in the ventral and dorsolateral prostate lobes of rats treated with finasteride, a 5-alpha reductase inhibitor. Prostate. 35:1998;157-164.
23. Epstein JI, Marks LS, and Partin AW: Histological changes in benign prostate biopsies following long-term finsteride therapy for benign prostatic hyperplasia. J Urol Pathol (in press).
24. Bartsch G., Muller H.R., Oberholzer M., et al. Light microscopic stereologic analysis of the normal prostate and of benign prostatic hyperplasia. J Urol. 122:1979;487-491.
25. Rohr H.P., Bartsch G. Human benign prostatic hyperplasia a stromal disease? New perspectives by quantitative morphology . Urology. 16:1980;625-633.
26. Shapiro E., Becich M.J., Hartanto V., et al. The realtive proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostatic hyperplasia. J Urol. 147:1992;1293-1297.
27. Marks L.S., Treiger B., Dorey F.J., et al. Morphometry of the prostate I.Distribution of tissue components in hyperplastic glands . Urology. 44:1994;486-492.
28. Lepor H., Wang B., Shapiro E. Relationship between prostatic epithelial volume and serum PSA levels. Urology. 44:1994;199-205.
29. Kalish J., Cooner W.H., Graham S.D. Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of prostate. Urology. 43:1994;601-606.
30. Hammerer P.G., McNeal J.E., Stamey T.A. Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate. J Urol. 153:1995;111-114.
31. Marks L.S., Dorey F.J., Rhodes T., et al. Serum PSA levels after TURP longitudinal characterization in men with BPH . J Urol. 156:1996;1035-1039.
32. Waldstreicher J., Roehrborn C.G., Boyle P., et al. Baseline serum PSA and prostate volume predict long-term symptomatic response to finasteride results of a four-year placebo-controlled trial (abstract) . J Urol. 159:(suppl A):1998;255A.
33. Boyle P., Gould A.L., Roehrborn C.G. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride. Urology. 48:1996;398-405.
34. Bramson H.N., Hermann D., Batchelor K.W., et al. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther. 282:1997;1496-1502.